MaxCyte reports preliminary FY2024 core revenue $32.2M-$32.4M, up 8-9% YoY

MAXCYTE, INC.

2024-FY EPS reported -$0.39 revenue$38,627,000

Q4 2024 core revenue expected $8.3M–$8.5M vs $7.2M in Q4 2023.
Full-year core revenue $32.2M–$32.4M, up 8–9% from $29.8M in FY2023.
Cash and investments ~$190M at Dec 31, 2024, above updated guidance of $185M.
Added six SPL customers in 2024; supported launch of first FDA-approved non-viral gene-edited cell therapy.
Audited FY2024 results expected in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.